MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-11-2022
Affimed N.V. Operating Cash Flow 2011-2026 | AFMD
Annual Operating Cash Flow Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 M | -19.4 M | -29.1 M | 49.4 M | -25.5 M | -32.1 M | -18.5 M | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.4 M | -86.6 M | -23.1 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-29.7 M | $ 2.52 | 23.89 % | $ 142 M |  China |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.36 | 2.75 % | $ 8.08 B |  Australia |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 25.95 | -0.75 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 233.74 | 2.23 % | $ 5 B |  Danmark |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 3.04 | 2.42 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
890 M | $ 116.71 | -1.49 % | $ 27.2 B | Germany |
 |
BioXcel Therapeutics
BTAI
|
-72 M | $ 1.83 | 1.1 % | $ 4.64 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.67 | -1.48 % | $ 16.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 67.88 | -2.46 % | $ 9.08 B | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.68 | -1.98 % | $ 1.55 B | Britain |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.43 | 6.57 % | $ 9.64 B | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Coherus BioSciences
CHRS
|
-175 M | $ 2.07 | 30.03 % | $ 195 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
2.88 B | $ 170.58 | -1.86 % | $ 24.8 B | USA |
 |
Bio-Path Holdings
BPTH
|
-11.5 M | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
-19 M | $ 1.22 | -2.4 % | $ 1.8 M | USA |
 |
Baudax Bio
BXRX
|
-27.8 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |